With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for ... the market for Gilead Sciences ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir ... with the drug in COVID-19 – by a research team in China – is due to report findings shortly. Studies are also ...

A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...

Below, check out the roundup of California Healthline’s coverage. For today's national health news, read KFF Health News’ Morning Briefing.